CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Shortwave Life Sciences PLC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Shortwave Life Sciences PLC
17 Hanover Square
Phone: +44 2038387621p:+44 2038387621 LONDON, W1S 1BN  United Kingdom Ticker: PSYPSY
Business Summary
Shortwave Life Sciences Plc is a biopharmaceutical company developing drug combinations and delivery methods to treat patients suffering from mental health disorders with a focus on eating disorders and anorexia nervosa. The Company has an interest in the area of psychedelic-based drug development, where it has developed a buccal-film based delivery platform and psilocybin-based drug combination for its initial eating disorders programme for anorexia nervosa. Its Anorexia program buccal film is fully developed and in clinical testing. It is focused on developing formulations containing multiple active compounds to maximize therapeutic benefits. Its psilocybin-based application programming interface (API) combination for anorexia nervosa offers an expanded mechanism of action aimed at addressing multiple receptors in the patient’s brain. Its first program targets treatment-resistant Anorexia Nervosa, addressing a critical area of unmet medical need.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
10/31/20244/30/2024Yes----

Industries
SIC Code Description
6719 Offices of holding companies, not elsewhere classified
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board Rolf AdGerritsen 62 7/29/2025 7/29/2025
Chief Operating Officer, Executive Director StephenMurphy 38 9/10/2025 6/21/2021
Executive Director Stephen J.Molloy 50 9/10/2025 7/29/2025
Company Secretary K.Mildwaters 5/3/2022 5/3/2022
Non-Executive Independent Director Ron C.Lipsky 49 7/29/2025 11/27/2024

General Information
Number of Employees: 1 (As of 4/30/2024)
Outstanding Shares: 378,290,760 (As of 10/31/2024)
Stock Exchange: AQS


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, October 15, 2025